Ignite Creation Date:
2024-05-06 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 12:23 PM
Study NCT ID:
NCT03136653
Status:
COMPLETED
Last Update Posted:
2021-08-25
First Post:
2017-04-18
Brief Title:
A Phase 2 Trial of MP0250 Plus Bortezomib Dexamethasone in Patients With Multiple Myeloma
Sponsor:
Molecular Partners AG
Organization:
Molecular Partners AG
Study Overview
Official Title:
A Phase 2 Open-label Single-arm Multicenter Trial of MP0250 Plus Bortezomib Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy safety tolerability pharmacokinetics PK immunogenicity and efficacy of MP0250 in combination with bortezomib dexamethasone in patients with refractory and relapsed multiple myeloma RRMM
MP0250 is a multi-DARPin drug candidate with three specificities able to simultaneously neutralize the activities of vascular endothelial growth factor VEGF and hepatocyte growth factor HGF and also to bind to human serum albumin HSA to give an increased plasma half-life and potentially enhanced tumor penetration
MP0250 is a multi-DARPin drug candidate with three specificities able to simultaneously neutralize the activities of vascular endothelial growth factor VEGF and hepatocyte growth factor HGF and also to bind to human serum albumin HSA to give an increased plasma half-life and potentially enhanced tumor penetration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-002771-10 | EUDRACT_NUMBER | None | None |